Clinical Trial

INterest of the Negative Predictive Value of Integrons in the reduCtion of Large Broad-spectrum anTibiotics Consumption for Urinary Tract infectionS

Study acronym: INVICTUS
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Urinary tract infections (UTI), mainly driven by Gram-negative bacteria (GNB) are a frequent cause of hospitalization and the second cause of antibiotic prescription after lower respiratory tract infections. Integrons play a major role in the dissemination of antibiotic resistance among GNB. In the prospective INVICTUS project, whose ultimate objective is to reduce the use of large broad-spectrum antibiotics, our hypothesis is that, in adult patients with a non-severe UTI (qSOFA\<2) and a former documentation with a 3GC-resistant GNB in the previous 6 months, integrons search could reduce the empirical use of large broad-spectrum antibiotics.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-23.
Trial Details
NCT Number NCT07675018
Lead Sponsor University Hospital, Limoges
Conditions Drug Resistance, Microbial, Biomarkers, Urinary Tract Infections (UTI's), Antibacterial Agents
Enrollment 204 participants
Start Date 2026-09-15
Primary Completion 2028-09-21 (estimated)
Study Completion 2028-09-21 (estimated)
Updated on ClinicalTrials.gov 2026-07-01